ACE阻害は,冠動脈疾患の患者における同情性冠動脈静脈収縮を弱める
1Cattedra di Medicina Interna (Ospedale S. Gerardo, Monza), Milan, Italy.
Circulation
|June 1, 1992
まとめ
アンジオテンシン変換酵素 (ACE) 阻害は,冠動脈疾患の患者の交感性冠動脈静脈収縮を減少させます. この効果は,冠動脈の血流調節に対するアンジオテンシンIIの影響を阻害している可能性が高い.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 生理学 生理学とは
背景:
- 交感刺激は通常,外周動脈の血管収縮を引き起こします.
- 血管新生変換酵素 (ACE) 阻害が同情性冠動脈静脈収縮に及ぼす影響は十分に理解されていません.
研究 の 目的:
- ACE阻害が冠動脈疾患の患者における交感性冠動脈静脈収縮を弱めるかどうかを調査する.
主な方法:
- 冠動脈動脈硬化症の9人の患者は,冷たい圧力のテストとダイビングの刺激を受けた.
- 測定には,動脈圧,心拍数,冠動脈副鼻腔血流 (CBF),冠動脈血管抵抗 (CVR) が含まれていた.
- カプトプリル (ACE阻害剤) の経口投与前後の測定が行われました.
主要な成果:
- カプトプリルなしで,交感刺激は冠動脈血管抵抗 (CVR) を増加させ,冠動脈血流 (CBF) を減少させた.
- カプトプリルは,刺激に対する血圧や心拍数の反応を有意に変化させなかった.
- カプトプリルは,交感刺激中にCVRの増加を著しく弱めた.
結論:
- ACE阻害は,冠動脈疾患の患者における同情性冠動脈静脈収縮を効果的に減少させます.
- この衰弱は,同情性冠動脈血管運動トーンに対するアンジオテンシンIIの促進作用の除去によって媒介される可能性が高い.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...